$680 Million is the total value of TANG CAPITAL MANAGEMENT LLC's 5 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ODT | Buy | ODONATE THERAPEUTICS INC | $262,893,000 | -13.8% | 12,412,338 | +1.7% | 38.64% | -20.1% |
| HRTX | Buy | HERON THERAPEUTICS INC | $238,692,000 | +55.8% | 8,648,252 | +2.1% | 35.08% | +44.5% |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO | $123,256,000 | +11.3% | 4,138,893 | +20.3% | 18.11% | +3.3% |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $55,603,000 | – | 2,965,485 | +100.0% | 8.17% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -2,328,279 | -100.0% | -9.85% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HERON THERAPEUTICS INC | 37 | Q3 2023 | 55.0% |
| LA JOLLA PHARMACEUTICAL CO | 34 | Q2 2022 | 37.1% |
| ROCKET PHARMACEUTICALS INC | 20 | Q3 2023 | 31.6% |
| BIOMARIN PHARMACEUTICAL INC | 18 | Q3 2017 | 12.1% |
| ODONATE THERAPEUTICS INC | 17 | Q4 2021 | 69.8% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 18.4% |
| COHERUS BIOSCIENCES INC | 15 | Q3 2023 | 2.7% |
| EQUILLIUM INC | 13 | Q3 2023 | 1.2% |
| RELMADA THERAPEUTICS INC | 12 | Q4 2022 | 6.2% |
| MIRATI THERAPEUTICS INC | 11 | Q3 2023 | 10.9% |
View TANG CAPITAL MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 4 | 2024-02-02 |
| 4 | 2023-12-18 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-10-13 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-06-01 |
| 4 | 2023-06-01 |
| 4 | 2023-05-30 |
View TANG CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.